COMPANY:

BD Biosci

"BD (Becton, Dickinson and Company)...announced a strategic partnership with Camtech Health, a digital health company focused on at-home health testing, to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample in the privacy of their own home."

"BD...and Techcyte...announced a strategic collaboration agreement to offer an AI-based algorithm that guides cytologists and pathologists to efficiently and effectively identify evidence of cervical cancer and precancer using whole-slide imaging...The agreement enables BD to deliver a complete solution that aims to reduce the potential for human error and enable greater throughput, so that labs can achieve their results with greater standardization, reproducibility, and efficiency from a Pap test, also known as a Pap smear."

"BD (Becton, Dickinson and Company)...announced a collaboration with the Kenyan Government through the National Cancer Institute-Kenya to advance access to critical cancer diagnostics for women in Kenya. Through this program, BD continues to drive its commitment toward progress of advancing health equity to underserved communities around the world."

"Novartis subsidiary Navigate Biopharma announced...that it has formed a strategic collaboration with Becton Dickinson to help develop and commercialize companion diagnostics and clinical decision-making tools using flow cytometry."

"BD (Becton, Dickinson and Company)...announced U.S. Food and Drug Administration (FDA) market approval for the BD Onclarity™ HPV Assay to be used with the ThinPrep® Pap Test...The inclusion of the ThinPrep® Pap Test improves access to the benefits of the BD human papillomavirus virus (HPV) assay, which is the only FDA-approved assay that tests for an extended set of HPV types individually, and particularly for HPV31, a specific type of HPV that poses a high-risk for causing cervical cancer."

"BD (Becton, Dickinson and Company)...announced a collaboration agreement with Labcorp...creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases...The agreement creates a framework for BD and Labcorp Drug Development to collaborate on flow cytometry-based CDx opportunities with pharmaceutical partners. The two companies bring together capabilities that comprise an end-to-end solution for CDx development for the pharmaceutical industry."

"BD (Becton, Dickinson and Company)...announced it has completed the acquisition of Cytognos, a privately held company headquartered in Salamanca, Spain, specializing in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection and immune monitoring research for blood diseases...Cytognos' key products increase BD's comprehensive portfolio of diagnostic and research solutions for certain types of cancers that use flow cytometry as the primary means of discovery, diagnosis and understanding, including lymphoma, leukemia and multiple myeloma."